CGP-53153 is a selective inhibitor of the Na⁺/K⁺-ATPase, particularly targeting the alpha-2 isoform. It is primarily used in research settings to study ion transport mechanisms in cardiac and neuronal cells, influencing cellular signaling, excitability, and metabolic processes. Investigations focus on its role in modulating pump activity relevant to cardiovascular function, neuroprotection, and conditions like heart failure or ischemia. Preclinical studies assess its efficacy and safety for potential therapeutic development in metabolic and neurological disorders.